Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient Population [0.03%]
艾伏尼布同情用药在意大利难治性慢性髓系白血病患者中的疗效分析
Massimo Breccia,Antonella Russo Rossi,Valentina Giai et al.
Massimo Breccia et al.
Chronic myeloid leukemia (CML) patients who have experienced failure and/or intolerance to multiple lines of treatment have limited therapeutic possibilities. Asciminib is a first-in-class tyrosine kinase inhibitor (TKI) that inhibits the A...
Fixed Duration Ibrutinib-Venetoclax, a Redefinition of the CLL Treatment Landscape [0.03%]
固定疗程的伊布替尼-维奈克拉联合治疗重新定义了慢性淋巴细胞白血病的治疗格局
Stefano Molica,David Allsup
Stefano Molica
The fixed-duration combination of ibrutinib and venetoclax (IV) has emerged as a highly effective therapeutic strategy for treating chronic lymphocytic leukemia (CLL), marking a significant shift in the treatment paradigm for this disease. ...
Survival Analysis in a Colombian Cohort of Mantle Cell Lymphoma. A Real-World Experience [0.03%]
哥伦比亚套细胞淋巴瘤队列的生存分析一种真实世界的经验研究
Juan F Combariza-Vallejo,Rocío Orduz-Rodriguez,Natalia Gomez-Lopera et al.
Juan F Combariza-Vallejo et al.
Mantle cell lymphoma is a type of B-cell lymphoma with limited epidemiologic data in Latin America. The main objective was evaluating survival, in mantle cell lymphoma in Colombia and the influence of hematopoietic stem cell transplantation...
Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study [0.03%]
年龄对边缘区淋巴瘤生物学、临床表现及结局的影响——多中心队列研究结果
Pallawi Torka,Natalie S Grover,Timothy J Voorhees et al.
Pallawi Torka et al.
Given the paucity of age-specific data about biology, presentation, and treatment outcomes in adults with MZL, we sought to evaluate differences between younger (≤ 70 years) and older (> 70 years) patients with MZL in a large retrospective...
Multicenter Study
Hematological oncology. 2025 May;43(3):e70087. DOI:10.1002/hon.70087 2025
Baseline, Drug-Related and Persistent Anemia and/or Thrombocytopenia Predict Responses and Prognosis in Myelofibrosis Patients Treated With Ruxolitinib [0.03%]
基线、药物相关性和持续性的贫血和/或血小板减少症可预测鲁索利替尼治疗原发性骨髓纤维化患者的疗效及预后
A Laganà,E Scalzulli,I Carmosino et al.
A Laganà et al.
ARAP1-AS1 Overexpression Increases Diffuse Large B Cell Lymphoma Progression by Sponging miR-508-5p to Activate the EMP1-PI3K/AKT Pathway [0.03%]
ARAP1-AS1过表达通过海绵吸附miR-508-5p激活EMP1-PI3K/AKT通路促进弥漫性大B细胞淋巴瘤进展
Yamei Chen,Minmin Ren,Lei Zhu et al.
Yamei Chen et al.
Diffuse large B cell lymphoma (DLBCL) is a type of common and fatal non-Hodgkin lymphoma. This study aimed to detect the specific function of lncRNA ARAP1-AS1 in DLBCL. The in vitro experiments were performed using RT-qPCR, western blotting...
Clinical Outcomes of CD7 CAR-T Cell Therapy in Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients [0.03%]
CD7 CAR-T细胞治疗复发或难治性T细胞急性淋巴细胞白血病和淋巴瘤的临床结果
Jinyan Xiao,Yujie Liu,Yifan Shen et al.
Jinyan Xiao et al.
Relapse and refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma (R/R T-ALL/LBL) patients have poor outcomes. Chimeric antigen receptor (CAR)-T-cell therapy for T-ALL/LBL has shown encouraging results in the early stage...
Circulating Levels of PF4/CXCL4 in Patients With BCR::ABL1-Negative Myeloproliferative Neoplasms: A New Potential Prognostic Factor for Disease Progression [0.03%]
BCR-ABL1阴性骨髓增生性肿瘤患者的循环PF4 / CXCL4水平：疾病进展的新的潜在预后因素
Valentina Bellani,Daniele Cattaneo,Vittorio Abbonante et al.
Valentina Bellani et al.
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: 14-Year Experience of an Academic Center [0.03%]
免疫球蛋白轻链淀粉样变性的临床表现及转归：一所学术中心14年的诊治经验
Danai Dima,Utkarsh Goel,Fauzia Ullah et al.
Danai Dima et al.
Localized light chain amyloidosis (loc-AL) is a rare disorder characterized by localized deposition of misfolded AL fibrils. There are limited data on patterns of disease presentation and long-term outcomes. In this study, we retrospectivel...
Long-Term Outcomes and Management Strategies With DA-R-EPOCH in Primary Mediastinal B-Cell Lymphoma: Insights From a Single-Center Experience [0.03%]
DA-R-EPOCH方案治疗原发纵隔B细胞淋巴瘤的长期疗效及管理策略：单中心经验分享
Robin Noel,Catalina Montes de Oca,Patrick Sfumato et al.
Robin Noel et al.
Immunochemotherapy has demonstrated high cure rates in primary mediastinal large B-cell lymphoma (PMBCL). Recent findings from the IELSG 37 study show that certain specific dose-dense treatment regimens are more likely to eliminate the need...
Observational Study
Hematological oncology. 2025 May;43(3):e70060. DOI:10.1002/hon.70060 2025